AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. STTK
  4. [Form 4] Shattuck Labs, Inc. Insider Trading Activity

[Form 4] Shattuck Labs, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Positive)
Form Type
4
Rhea-AI Filing Summary

Shattuck Labs reported a private placement on 08/25/2025 in which accredited investors led by OrbiMed vehicles purchased an aggregate of 6,306,127 shares of common stock and received pre-funded warrants to buy up to 12,133,661 shares plus accompanying common warrants to buy up to 18,439,799 shares. The price per share with an accompanying common warrant was $0.8677; the pre-funded warrant price with an accompanying common warrant was $0.8676. Pre-funded warrants are immediately exercisable subject to a 9.99% beneficial ownership blocker. The report was filed by Mona Ashiya, identified as a director, who disclaims beneficial ownership of the securities except to the extent of pecuniary interest, and the securities are held of record by OrbiMed funds and related entities.

Shattuck Labs ha comunicato un collocamento privato il 25/08/2025 nel quale investitori accreditati, guidati da veicoli OrbiMed, hanno acquistato in totale 6.306.127 azioni ordinarie e hanno ricevuto warrant prefinanziati per acquistare fino a 12.133.661 azioni, oltre a warrant comuni aggiuntivi per acquistare fino a 18.439.799 azioni. Il prezzo per azione con un warrant comune allegato era di $0,8677; il prezzo del warrant prefinanziato con warrant comune allegato era di $0,8676. I warrant prefinanziati sono immediatamente esercitabili, soggetti a un blocco del 9,99% sulla titolarit脿 beneficiaria. La segnalazione 猫 stata presentata da Mona Ashiya, indicata come direttrice, che dichiara di non avere la titolarit脿 beneficiaria dei titoli salvo per l'interesse pecuniario, e i titoli risultano detenuti a registro da fondi OrbiMed e entit脿 correlate.

Shattuck Labs inform贸 una colocaci贸n privada el 25/08/2025 en la que inversores acreditados, liderados por veh铆culos de OrbiMed, adquirieron en conjunto 6.306.127 acciones ordinarias y recibieron warrants prefinanciados para comprar hasta 12.133.661 acciones, adem谩s de warrants comunes adicionales para comprar hasta 18.439.799 acciones. El precio por acci贸n con un warrant com煤n adjunto fue de $0,8677; el precio del warrant prefinanciado con warrant com煤n adjunto fue de $0,8676. Los warrants prefinanciados son ejercitables de inmediato, sujetos a un bloqueo del 9,99% de la propiedad beneficiaria. El informe fue presentado por Mona Ashiya, identificada como directora, quien renuncia a la titularidad beneficiaria de los valores salvo en la medida de su inter茅s pecuniario, y los valores est谩n registrados a nombre de fondos y entidades relacionadas de OrbiMed.

Shattuck Labs電� 2025-08-25鞐� 靷 氚滍枆鞚� 氤搓碃頄堨姷雼堧嫟. OrbiMed 甏�霠� 旮瓣磤鞚� 欤茧弰頃� 瓿奠澑 韴瀽鞛愲摛鞚� 頃╆硠 6,306,127欤�鞚� 氤错喌欤茧ゼ 毵れ垬頄堦碃, 斓滊寑 12,133,661欤�毳� 毵れ垬頃� 靾� 鞛堧姅 頂勲Μ韼�霐旊摐 鞗岆煱韸胳檧 於旉皜搿� 斓滊寑 18,439,799欤�毳� 毵れ垬頃� 靾� 鞛堧姅 氤错喌欤� 鞗岆煱韸鸽ゼ 氚涭晿鞀惦媹雼�. 氤错喌欤� 鞗岆煱韸戈皜 靾橂皹霅� 欤茧嫻 臧�瓴╈潃 $0.8677鞓�瓿�, 氤错喌欤� 鞗岆煱韸戈皜 靾橂皹霅� 頂勲Μ韼�霐旊摐 鞗岆煱韸� 臧�瓴╈潃 $0.8676鞓�鞀惦媹雼�. 頂勲Μ韼�霐旊摐 鞗岆煱韸鸽姅 歃夓嫓 頄夓偓 臧�電ロ晿雮� 9.99%鞚� 鞁れ唽鞙� 歆�攵� 彀嫧鞛レ箻臧� 鞝侅毄霅╇媹雼�. 氤搓碃靹滊姅 鞚挫偓搿� 旮办灛霅� Mona Ashiya臧� 鞝滌稖頄堨溂氅�, 攴鸽厐電� 旮堨爠鞝� 鞚挫澋 氩旍渼毳� 鞝滌櫢頃� 鞙犼皜歃濌秾鞚� 鞁れ唽鞙犽ゼ 攵�鞚疙晿瓿� 鞛堦碃, 頃措嫻 歃濌秾鞚� OrbiMed 韼�霌� 氚� 甏�霠� 旮瓣磤 氇呾潣搿� 霌标赴霅橃柎 鞛堨姷雼堧嫟.

Shattuck Labs a d茅clar茅 un placement priv茅 le 25/08/2025 dans lequel des investisseurs accr茅dit茅s, men茅s par des v茅hicules OrbiMed, ont achet茅 au total 6 306 127 actions ordinaires et ont re莽u des warrants pr茅financ茅s leur permettant d'acheter jusqu'脿 12 133 661 actions, ainsi que des warrants ordinaires suppl茅mentaires pour acheter jusqu'脿 18 439 799 actions. Le prix par action avec un warrant ordinaire accompagn茅 茅tait de $0,8677 ; le prix du warrant pr茅financ茅 avec warrant ordinaire accompagn茅 茅tait de $0,8676. Les warrants pr茅financ茅s sont imm茅diatement exer莽ables, sous r茅serve d'un verrouillage de 9,99% de la propri茅t茅 b茅n茅ficiaire. Le rapport a 茅t茅 d茅pos茅 par Mona Ashiya, identifi茅e comme administratrice, qui d茅cline la propri茅t茅 b茅n茅ficiaire des titres sauf dans la mesure d'un int茅r锚t p茅cuniaire, et les titres sont d茅tenus au registre par des fonds OrbiMed et des entit茅s affili茅es.

Shattuck Labs meldete eine Privatplatzierung am 25.08.2025, bei der akkreditierte Investoren unter F眉hrung von OrbiMed-Fahrzeugen insgesamt 6.306.127 Stammaktien erwarben und vorrangig finanzierte Warrants zum Kauf von bis zu 12.133.661 Aktien sowie zus盲tzliche Stammwarrants zum Erwerb von bis zu 18.439.799 Aktien erhielten. Der Preis pro Aktie mit begleitendem Stammwarrant betrug $0,8677; der Preis des vorrangig finanzierten Warrants mit begleitendem Stammwarrant betrug $0,8676. Vorrangig finanzierte Warrants sind sofort aus眉bbar, unterliegen jedoch einer 9,99% Sperre des wirtschaftlichen Eigentums. Der Bericht wurde von Mona Ashiya eingereicht, die als Direktorin bezeichnet ist und das wirtschaftliche Eigentum an den Wertpapieren au脽er im Rahmen eines pecuni盲ren Interesses bestreitet; die Wertpapiere sind auf OrbiMed-Fonds und zugeh枚rige Einheiten eingetragen.

Positive
  • Material capital raise: Issuer sold shares and warrants to accredited investors, providing immediate funding.
  • Pre-funded warrants allow investors to limit immediate dilution until exercised.
  • Detailed disclosure of entity relationships and beneficial ownership disclaimers enhances transparency.
Negative
  • Potential dilution: Warrants could convert into a large number of shares (up to 18,439,799), creating future overhang.
  • Low unit price: Pricing at ~$0.8677 per share/unit may reflect downward pressure on equity valuation.
  • Immediate exercisability of pre-funded warrants (subject to blocker) could lead to concentrated ownership changes if exercised.

Insights

TL;DR: Company raised capital via a private placement led by OrbiMed, creating significant warrant overhang but providing immediate cash at sub-$1 pricing.

The private placement injected cash into the company through sale of common shares and a mix of pre-funded warrants and common warrants. Aggregate figures are material relative to typical micro/small-cap financings: 6.3 million shares plus pre-funded warrants for 12.1 million shares and warrants for 18.4 million shares, priced at about $0.87 per unit. The pre-funded warrants reduce immediate dilution until exercised but are exercisable now subject to a 9.99% blocker. The multi-party ownership structure and disclaimers indicate that OrbiMed-affiliated entities hold record title while investment and voting power is routed through OrbiMed Advisors. This transaction likely improves near-term liquidity while creating a meaningful potential share overhang contingent on future warrant exercises.

TL;DR: Reporting shows standard institutional placement mechanics with customary manager disclosures and beneficial ownership disclaimers.

The Form 4 discloses that record ownership rests with OrbiMed funds and that OrbiMed Advisors, GP entities, and a management committee may be deemed to have voting and investment power, while each party disclaims beneficial ownership except for pecuniary interest. Mona Ashiya is identified as a director filing the Form 4, and the filing includes the required signature and explanatory footnotes clarifying relationships among OrbiMed entities. From a governance perspective, disclosures align with Rule 16 reporting practices and clarify chain-of-control without asserting direct beneficial ownership by the director.

Shattuck Labs ha comunicato un collocamento privato il 25/08/2025 nel quale investitori accreditati, guidati da veicoli OrbiMed, hanno acquistato in totale 6.306.127 azioni ordinarie e hanno ricevuto warrant prefinanziati per acquistare fino a 12.133.661 azioni, oltre a warrant comuni aggiuntivi per acquistare fino a 18.439.799 azioni. Il prezzo per azione con un warrant comune allegato era di $0,8677; il prezzo del warrant prefinanziato con warrant comune allegato era di $0,8676. I warrant prefinanziati sono immediatamente esercitabili, soggetti a un blocco del 9,99% sulla titolarit脿 beneficiaria. La segnalazione 猫 stata presentata da Mona Ashiya, indicata come direttrice, che dichiara di non avere la titolarit脿 beneficiaria dei titoli salvo per l'interesse pecuniario, e i titoli risultano detenuti a registro da fondi OrbiMed e entit脿 correlate.

Shattuck Labs inform贸 una colocaci贸n privada el 25/08/2025 en la que inversores acreditados, liderados por veh铆culos de OrbiMed, adquirieron en conjunto 6.306.127 acciones ordinarias y recibieron warrants prefinanciados para comprar hasta 12.133.661 acciones, adem谩s de warrants comunes adicionales para comprar hasta 18.439.799 acciones. El precio por acci贸n con un warrant com煤n adjunto fue de $0,8677; el precio del warrant prefinanciado con warrant com煤n adjunto fue de $0,8676. Los warrants prefinanciados son ejercitables de inmediato, sujetos a un bloqueo del 9,99% de la propiedad beneficiaria. El informe fue presentado por Mona Ashiya, identificada como directora, quien renuncia a la titularidad beneficiaria de los valores salvo en la medida de su inter茅s pecuniario, y los valores est谩n registrados a nombre de fondos y entidades relacionadas de OrbiMed.

Shattuck Labs電� 2025-08-25鞐� 靷 氚滍枆鞚� 氤搓碃頄堨姷雼堧嫟. OrbiMed 甏�霠� 旮瓣磤鞚� 欤茧弰頃� 瓿奠澑 韴瀽鞛愲摛鞚� 頃╆硠 6,306,127欤�鞚� 氤错喌欤茧ゼ 毵れ垬頄堦碃, 斓滊寑 12,133,661欤�毳� 毵れ垬頃� 靾� 鞛堧姅 頂勲Μ韼�霐旊摐 鞗岆煱韸胳檧 於旉皜搿� 斓滊寑 18,439,799欤�毳� 毵れ垬頃� 靾� 鞛堧姅 氤错喌欤� 鞗岆煱韸鸽ゼ 氚涭晿鞀惦媹雼�. 氤错喌欤� 鞗岆煱韸戈皜 靾橂皹霅� 欤茧嫻 臧�瓴╈潃 $0.8677鞓�瓿�, 氤错喌欤� 鞗岆煱韸戈皜 靾橂皹霅� 頂勲Μ韼�霐旊摐 鞗岆煱韸� 臧�瓴╈潃 $0.8676鞓�鞀惦媹雼�. 頂勲Μ韼�霐旊摐 鞗岆煱韸鸽姅 歃夓嫓 頄夓偓 臧�電ロ晿雮� 9.99%鞚� 鞁れ唽鞙� 歆�攵� 彀嫧鞛レ箻臧� 鞝侅毄霅╇媹雼�. 氤搓碃靹滊姅 鞚挫偓搿� 旮办灛霅� Mona Ashiya臧� 鞝滌稖頄堨溂氅�, 攴鸽厐電� 旮堨爠鞝� 鞚挫澋 氩旍渼毳� 鞝滌櫢頃� 鞙犼皜歃濌秾鞚� 鞁れ唽鞙犽ゼ 攵�鞚疙晿瓿� 鞛堦碃, 頃措嫻 歃濌秾鞚� OrbiMed 韼�霌� 氚� 甏�霠� 旮瓣磤 氇呾潣搿� 霌标赴霅橃柎 鞛堨姷雼堧嫟.

Shattuck Labs a d茅clar茅 un placement priv茅 le 25/08/2025 dans lequel des investisseurs accr茅dit茅s, men茅s par des v茅hicules OrbiMed, ont achet茅 au total 6 306 127 actions ordinaires et ont re莽u des warrants pr茅financ茅s leur permettant d'acheter jusqu'脿 12 133 661 actions, ainsi que des warrants ordinaires suppl茅mentaires pour acheter jusqu'脿 18 439 799 actions. Le prix par action avec un warrant ordinaire accompagn茅 茅tait de $0,8677 ; le prix du warrant pr茅financ茅 avec warrant ordinaire accompagn茅 茅tait de $0,8676. Les warrants pr茅financ茅s sont imm茅diatement exer莽ables, sous r茅serve d'un verrouillage de 9,99% de la propri茅t茅 b茅n茅ficiaire. Le rapport a 茅t茅 d茅pos茅 par Mona Ashiya, identifi茅e comme administratrice, qui d茅cline la propri茅t茅 b茅n茅ficiaire des titres sauf dans la mesure d'un int茅r锚t p茅cuniaire, et les titres sont d茅tenus au registre par des fonds OrbiMed et des entit茅s affili茅es.

Shattuck Labs meldete eine Privatplatzierung am 25.08.2025, bei der akkreditierte Investoren unter F眉hrung von OrbiMed-Fahrzeugen insgesamt 6.306.127 Stammaktien erwarben und vorrangig finanzierte Warrants zum Kauf von bis zu 12.133.661 Aktien sowie zus盲tzliche Stammwarrants zum Erwerb von bis zu 18.439.799 Aktien erhielten. Der Preis pro Aktie mit begleitendem Stammwarrant betrug $0,8677; der Preis des vorrangig finanzierten Warrants mit begleitendem Stammwarrant betrug $0,8676. Vorrangig finanzierte Warrants sind sofort aus眉bbar, unterliegen jedoch einer 9,99% Sperre des wirtschaftlichen Eigentums. Der Bericht wurde von Mona Ashiya eingereicht, die als Direktorin bezeichnet ist und das wirtschaftliche Eigentum an den Wertpapieren au脽er im Rahmen eines pecuni盲ren Interesses bestreitet; die Wertpapiere sind auf OrbiMed-Fonds und zugeh枚rige Einheiten eingetragen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ashiya Mona
(Last) (First) (Middle)
C/O SHATTUCK LABS, INC
500 W 5TH ST.
(Street)
AUSTIN TX 78701
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Shattuck Labs, Inc. [ STTK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/25/2025 P 5,255,106 A $0.8677 5,255,106 I See Footnote(3)(5)
Common Stock 08/25/2025 P 1,051,021 A $0.8677 1,051,021 I See Footnote(4)(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Pre-Funded Warrants (right to buy) $0.0001 08/25/2025 P 10,111,384 (2) (2) Common Stock 10,111,384 (1) 10,111,384 I See Footnote(3)(5)
Pre-Funded Warrants (right to buy) $0.0001 08/25/2025 P 2,022,277 (2) (2) Common Stock 2,022,277 (1) 2,022,277 I See Footnote(4)(5)
Common Warrants (right to buy) $1.0846 08/25/2025 P 15,366,490 (2) (2) Common Stock 15,366,490 (1) 15,366,490 I See Footnote(3)(5)
Common Warrants (right to buy) $1.0846 08/25/2025 P 3,073,298 (2) (2) Common Stock 3,073,298 (1) 3,073,298 I See Footnote(4)(5)
Explanation of Responses:
1. On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP ("OPI IX") and OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund") in a private placement which closed on August 25, 2025 (the "Closing Date") an aggregate of 6,306,127 shares of the Issuer's common stock ("Shares") and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676.
2. The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.
3. These securities are held of record by OPI IX. OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX.
4. These securities are held of record by Genesis Master Fund. OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
5. Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
/s/ Mona Ashiya 09/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did the Form 4 filed for STTK report?

The Form 4 reports a private placement closed 08/25/2025 involving issuance of 6,306,127 common shares, pre-funded warrants to purchase 12,133,661 shares, and common warrants to purchase 18,439,799 shares.

Who are the investors named in the filing for STTK?

OrbiMed Private Investments IX, LP and OrbiMed Genesis Master Fund, L.P. are the record holders of the issued securities as disclosed.

What prices were paid per security in the transaction?

Price per share with a common warrant: $0.8677; price per pre-funded warrant with a common warrant: $0.8676.

Are the pre-funded warrants exercisable immediately for STTK?

Yes, the pre-funded warrants are exercisable at any time after issuance, subject to a 9.99% beneficial ownership blocker.

Who filed the Form 4 and what is their relationship to the issuer?

Mona Ashiya filed the Form 4 and is identified on the form as a director; the filing includes disclaimers that the reporting person disclaims beneficial ownership except for pecuniary interest.
Stock STTK logo
Shattuck Labs, Inc.

NASDAQ:STTK

STTK Rankings

#5321 Ranked by Market Cap
N/A Ranked by Dividends
#20 Top Gainer

STTK Latest News

Aug 26, 2025
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
Aug 21, 2025
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
Aug 14, 2025
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Aug 5, 2025
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
Jul 2, 2025
Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

STTK Latest SEC Filings

Sep 2, 2025
[SCHEDULE 13D] Shattuck Labs, Inc. SEC Filing
Sep 2, 2025
[Form 4] Shattuck Labs, Inc. Insider Trading Activity
Sep 2, 2025
[Form 3] Shattuck Labs, Inc. Initial Statement of Beneficial Ownership
Sep 2, 2025
[Form 4] Shattuck Labs, Inc. Insider Trading Activity
Sep 2, 2025
[Form 4] Shattuck Labs, Inc. Insider Trading Activity

STTK Stock Data

46.98M
40.71M
14.36%
59.03%
0.9%
Biotechnology
Pharmaceutical Preparations
United States
AUSTIN